Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe

Scientists from Germany have recently identified a new sub-lineage of the alpha variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in some European countries. This sub-lineage harbors additional mutations in the nucleoprotein, spike protein, and open-reading frame 8 (ORF8). The variant with spike mutations is 3-fold less sensitive to neutralization by coronavirus disease 2019 (COVID-19) vaccine-induced antibodies. The study is currently available on the medRxiv* preprint server.

Study: Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants. Image Credit: iunewind/ ShutterstockStudy: Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants. Image Credit: iunewind/ Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

The alpha variant (B.1.1.7) of SARS-CoV-2 was first detected in the UK in September 2020. With significantly higher transmissibility than previously circulating strains, the alpha variant caused a sharp rise in new COVID-19 cases in the UK between February and May 2021. The original alpha variant is characterized by 17 mutations on the spike protein, ORF lab, ORF8, and nucleoprotein.

In Germany, continuous genomic surveillance was started in January 2021 to identify newly emerging viral variants and characterize the dynamics of viral spread at the local-, national-, and global levels.

In the current study, the scientists have identified a new sub-lineage of the alpha variant through genomic epidemiology analyses that they conducted weekly using viral isolates collected from a border region between Germany, Poland, and the Czech Republic.

They have determined the evolution, transmission dynamics, and immune escape ability of this sub-lineage by conducting phylogenetic analysis, epidemiological analysis, virus neutralization assay, and viral growth kinetics.

Identification of alpha sub-lineage

The scientists sequenced 948,077 alpha variant genomes and identified a specific sub-lineage that carries two additional mutations. These mutations are G204P on nucleoprotein and K68stop on ORF8. This sub-lineage showed an unequal distribution pattern. It accounted for 60 – 95% of all alpha-related cases in the Czech Republic, Hungary, Slovakia, and Austria. In contrast, about 10 – 35% of cases in Germany, Denmark, Switzerland, Poland, and France, and less than 10% of cases in Belgium and the Netherlands were associated with this sub-lineage. In the UK, it was associated with only 0.4% of all alpha cases.  

Transmission dynamics of alpha sub-lineage

The sub-lineage was identified first in November 2020 in Switzerland, Austria, France, Slovakia, and Denmark. However, it started circulating in 23 European countries by the end of January 2021. In the Czech Republic, the sub-lineage was first identified in January 2021 and soon became dominant. Between January and April 2021, the ratio of alpha sub-lineage to all alpha variants in the Czech Republic was 91 – 100%.

Signature mutations

The most common signature mutations found in the alpha sub-lineage were the same as the signature mutations found in the original alpha variant. Only two additional mutations G204P and K68stop were detected on nucleoprotein and ORF8, respectively.

Furthermore, extensive sequencing analysis identified another variant of the alpha sub-lineage carrying two additional spike mutations (D138Y and A701V). The D138Y spike mutation found in this new variant is one of the signature mutations of the SARS-CoV-2 gamma variant. Similarly, the A701V spike mutation is one signature mutation of the beta variant. This new variant of alpha sub-lineage was primarily detected in Germany and accounted for 50% of all alpha-related vaccine breakthrough cases.

Functional characterization of alpha sub-lineage

The scientists tested the susceptibility of the original alpha variant, alpha sub-lineage, and spike mutation-containing sub-lineage to neutralization by BNT162b2 COVID-19 vaccine-induced antibodies. The findings revealed that the alpha sub-lineage with two spike mutations is 3.2-fold less susceptible to antibody-mediated neutralization than the original alpha variant and alpha sub-lineage.

Regarding the replication rate in lung epithelial cells, the spike mutation-containing variant showed reduced fitness compared to the other two tested variants.

Study significance

The study identifies a novel sub-lineage of the SARS-CoV-2 alpha variant that contains two additional mutations in the nucleoprotein and ORF8. This variant has caused a surge in new COVID-19 cases in some European countries, especially the Czech Republic.

Moreover, the study identifies another variant of this alpha sub-lineage that contains two additional spike mutations. This new variant is relatively less susceptible to antibody-mediated neutralization. However, because of the reduced replication fitness, this variant is expected to have lower transmissibility.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 8 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2023, May 08). Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe. News-Medical. Retrieved on November 13, 2024 from https://www.news-medical.net/news/20211104/Identification-of-novel-SARS-CoV-2-alpha-variant-sub-lineage-in-Europe.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe". News-Medical. 13 November 2024. <https://www.news-medical.net/news/20211104/Identification-of-novel-SARS-CoV-2-alpha-variant-sub-lineage-in-Europe.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe". News-Medical. https://www.news-medical.net/news/20211104/Identification-of-novel-SARS-CoV-2-alpha-variant-sub-lineage-in-Europe.aspx. (accessed November 13, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2023. Identification of novel SARS-CoV-2 alpha variant sub-lineage in Europe. News-Medical, viewed 13 November 2024, https://www.news-medical.net/news/20211104/Identification-of-novel-SARS-CoV-2-alpha-variant-sub-lineage-in-Europe.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Leritrelvir shows high efficacy against SARS-CoV-2 protease mutations